INJEX Pharma AG
INJEX Pharma AG: Strategic Financial Group invests in INJEX Pharma AG
INJEX Pharma AG / Key word(s): Miscellaneous Corporate News: Strategic Financial Group invests in INJEX Pharma AG Berlin, December 17, 2013 – INJEX Pharma AG anounces, that Fambrinia Ltd. (Fambrinia) has taken a significant share in the Berlin based company and has become the largest shareholder in INJEX Pharma AG. Fambrinia holds the distribution rights for Injex Pharma products in Russia, Kazachstan, Azerbaijan, Belorussia and Turkmenistan. The respective contracts have been signed last Friday. The previously signed term sheet between the parties was already announced in an ad hoc news by INJEX Pharma last week. Fambrinia subscribes all newly issued ordinary shares of a 10% capital increase decided by the Executive Board and authorized by the Supervisory Board. Following this capital increase, the company’s share capital rises from EUR 3,458,000.00 to EUR 3,803,800.00, divided into 3,803,800 shares at a nominal value of EUR 1.00 per share. The issue price per share is set at EUR 1.00. The new shares carry full dividend rights from 1 January 2013. The new shares will be issued in private placement without pre-emptive rights. Furthermore, Fambrinia acquires a majority of the shares currently held by MMB Medical Marketing Berlin GmbH (MMB), so far the major shareholder of INJEX Pharma AG. MMB will transfer the most of the sales proceeds as a shareholder loan to INJEX Pharma AG. The proceeds from this transaction will mainly be used to reduce the companies liabilities and to further develop its operations. Upon consummation of the transaction, Fambrinia will held 40% of INJEX Pharma shares and become be the major shareholder, followed by MMB holding 14% of the shares. ‘We are very pleased having attracted Fambrinia as a strategic investor, who will provide us with growth capital as well as with valuable input for the future development for our products and applications since Fambrinia is our distributor for the huge markets in CIS countries.’ commented Dr. Thomas Klaue, CEO of INJEX Pharma AG. Dr. Peter Heinrich, Chairman of the Supervisory Board, adds: ‘With this transaction, the Management Board, which took office in last May, has concluded most of the necessary reorganization and restructuring of INJEX Pharma and can now focus on our operating business, mainly on the production development and the expansion of the international partner and distributor network.’ For further information on INJEX Pharma AG and its subsidiaries, please refer to www.injex.com. For further questions please contact our Investor Relations team directly: INJEX Pharma AG INJEX Pharma AG: INJEX Pharma Aktiengesellschaft and its subsidiaries INJEX Pharma GmbH and INJEX Vertrieb Deutschland GmbH are specialized in the development, manufacturing and marketing in the medical technology segment and in the cosmetics and beauty markets. The Group’s core business areas are the needle-free INJEX30 system and the product line SHIREEN in the beauty market. The main markets of the Group are North America, China, India, Russia and Europe. End of Corporate News 17.12.2013 Dissemination of a Corporate News, transmitted by DGAP – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | INJEX Pharma AG | |
Buckower Damm 114 | ||
12349 Berlin | ||
Germany | ||
Phone: | +49 89 24 41 18 – 223 | |
Fax: | +49 89 24 41 18 – 499 | |
E-mail: | ir@injex.de | |
Internet: | www.injex.de | |
ISIN: | DE000A0STYL7 | |
WKN: | A0STYL | |
Listed: | Regulierter Markt in Frankfurt (General Standard) | |
Notierung im Regulierten Markt vorgesehen / intended to be listed at Regulated Market |
End of News | DGAP News-Service |
245122 17.12.2013 |